[HTML][HTML] TGF-beta-activated cancer-associated fibroblasts limit cetuximab efficacy in preclinical models of head and neck cancer
Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …
[HTML][HTML] Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer
Purpose To investigate if cetuximab induces epithelial to mesenchymal transition (EMT) and
activation of cancer associated fibroblast (CAF) in the tumors of patients with squamous cell …
activation of cancer associated fibroblast (CAF) in the tumors of patients with squamous cell …
Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer
K Klinghammer, R Otto, JD Raguse… - … Journal of Cancer, 2017 - Wiley Online Library
Cetuximab is the single targeted therapy approved for the treatment of head and neck
cancer (HNSCC). Predictive biomarkers have not been established and patient stratification …
cancer (HNSCC). Predictive biomarkers have not been established and patient stratification …
Cancer-associated fibroblasts induce matrix metalloproteinase–mediated cetuximab resistance in head and neck squamous cell carcinoma cells
AC Johansson, A Ansell, F Jerhammar, MB Lindh… - Molecular cancer …, 2012 - AACR
A growing body of evidence suggests that components of the tumor microenvironment,
including cancer-associated fibroblasts (CAF), may modulate the treatment sensitivity of …
including cancer-associated fibroblasts (CAF), may modulate the treatment sensitivity of …
[HTML][HTML] Comprehensive molecular landscape of cetuximab resistance in head and neck cancer cell lines
INF Gomes, RJ da Silva-Oliveira, LS da Silva… - Cells, 2022 - mdpi.com
Cetuximab is the sole anti-EGFR monoclonal antibody that is FDA approved to treat head
and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of …
and neck squamous cell carcinoma (HNSCC). However, no predictive biomarkers of …
[HTML][HTML] Integrated single-cell and bulk gene expression and ATAC-seq reveals heterogeneity and early changes in pathways associated with resistance to cetuximab …
Background Identifying potential resistance mechanisms while tumour cells still respond to
therapy is critical to delay acquired resistance. Methods We generated the first …
therapy is critical to delay acquired resistance. Methods We generated the first …
Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab
M Iida, TM Brand, MM Starr, C Li, EJ Huppert, N Luthar… - Neoplasia, 2013 - Elsevier
The epidermal growth factor receptor (EGFR) is a central regulator of tumor progression in a
variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been …
variety of human cancers. Cetuximab is an anti-EGFR monoclonal antibody that has been …
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism
F Braig, M Kriegs, M Voigtlaender, B Habel, T Grob… - Cancer research, 2017 - AACR
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-
targeting drug cetuximab poses a challenge to their effective clinical management. Here, we …
targeting drug cetuximab poses a challenge to their effective clinical management. Here, we …
[HTML][HTML] Resistance of oral squamous cell carcinoma cells to cetuximab is associated with EGFR insensitivity and enhanced stem cell-like potency
Y Ohnishi, Y Minamino, K Kakudo… - Oncology …, 2014 - spandidos-publications.com
Cetuximab, a specific anti-epidermal growth factor receptor (EGFR) monoclonal antibody, is
used in cancer treatment. Although development of resistance to cetuximab is well …
used in cancer treatment. Although development of resistance to cetuximab is well …
[HTML][HTML] The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy
H Zaryouh, I De Pauw, H Baysal, P Pauwels… - Frontiers in …, 2021 - frontiersin.org
The epidermal growth factor receptor (EGFR) is a therapeutic target in head and neck
squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as …
squamous cell carcinoma (HNSCC). Resistance to EGFR-targeted therapies, such as …
相关搜索
- cetuximab efficacy tgf beta
- cetuximab efficacy neck cancer
- neck cancer patients with head
- neck cancer cetuximab treatment
- neck cancer cetuximab resistance
- neck cancer cell lines
- neck cancer mesenchymal transition
- matrix metalloproteinase cetuximab resistance
- neck cancer basal subtype
- cell lines atac seq
- cell lines early changes
- neck cancer tgf beta
- cell head cetuximab treatment
- basal subtype cetuximab treatment
- cell head basal subtype
- patients with head mesenchymal transition